Shares of Cadila Healthcare hit a record high on USFDA approval.
The stock jumped as much as 9.9 per cent to a record high.
The product will be manufactured at Moraiya manufacturing facility in India for US market.
Lialda (mesalamine) is indicated for the treatment of mild to moderate ulcerative colitis, a chronic condition that causes inflammation in the digestive tract.
Over 3.4 million shares change hands as of 0419 GMT, thrice the average 30-day trading volume.